DUO-MEDIHALER
LOE Approachingisoproterenol hydrochloride; phenylephrine bitartrate
NDAINHALATIONAEROSOL, METERED
Approved
Aug 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
DUO-MEDIHALER (isoproterenol hydrochloride; phenylephrine bitartrate). Approved for to improve hemodynamic status. First approved in 1973.
Drug data last refreshed 5d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DUO-MEDIHALER is a metered-dose aerosol combination of isoproterenol hydrochloride (beta-2 agonist) and phenylephrine bitartrate (alpha-1 agonist) approved in 1973 for inhalation use. It is indicated to improve hemodynamic status in patients requiring sympathomimetic support. The dual mechanism combines bronchodilation and vasoconstriction to enhance cardiovascular and respiratory function.
LOE Approaching
As an aging product approaching loss of exclusivity with minimal recent commercial investment, career opportunities on this brand are limited and declining.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
Working on DUO-MEDIHALER offers limited career growth potential given its LOE-approaching status and minimal linked job openings. This role is suited for professionals managing legacy portfolios or seeking stable, low-intensity assignments rather than high-impact commercial launches.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.